This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Danaher Corporation is a global conglomerate that designs, manufactures and markets diverse lines of professional, industrial, commercial and consumer products.
Yes, You Can Time the Market. Find out How - October 28, 2019
by Zacks Equity Research
Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?
Danaher (DHR) Beats Q3 Earnings Estimates, Lowers '19 View
by Zacks Equity Research
Danaher's (DHR) third-quarter 2019 earnings benefit from organic sales growth, acquisitions and DBS initiatives. It lowers 2019 projection, accounting for the Envista transaction.
Danaher (DHR) Q3 Earnings Surpass Estimates
by Zacks Equity Research
Danaher (DHR) delivered earnings and revenue surprises of 0.87% and -0.06%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Danaher (DHR) Ahead of Earnings?
by Zacks Equity Research
Danaher (DHR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Can Danaher (DHR) Keep Earnings Beat Streak Alive in Q3?
by Zacks Equity Research
Danaher's (DHR) third-quarter earnings are expected to reflect the impact of Danaher Business System, acquired assets, solid product offerings and innovation. Forex and cost woes remain.
Danaher (DHR) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Danaher (DHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Reasons Why Investors Should Avoid 3M (MMM) Stock for Now
by Zacks Equity Research
3M (MMM) suffers from weakness in organic sales, high costs of sales, forex woes and high debts. Fall in cash flow generation is also concerning.
Danaher (DHR) Earnings Expected to Grow: What to Know Ahead of Q3 Release
by Zacks Equity Research
Danaher (DHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Honeywell Unveils New Hearing Solution for Worker Safety
by Zacks Equity Research
Honeywell's (HON) VeriShield Smart Hearing Solution will assist companies in improving their hearing conservation programs with a personalized approach to worker protection.
GE to Offer Onshore Wind Turbine Solution to EDF Renewables
by Zacks Equity Research
General Electric's (GE) onshore wind turbine solution - Cypress platform - is likely to make EDF Renewables' Ventos da Bahia wind farm more efficient in producing renewable energy in Brazil.
Simple Market Timing Strategies That Work - October 09, 2019
by Zacks Equity Research
In the long-run, does consistent market timing really matter to be a successful investor?
Will Danaher (DHR) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Honeywell's (HON) Board Approves 10% Hike in Dividend Rate
by Zacks Equity Research
Honeywell's (HON) latest hike marks its 10th double digit increment in dividend rate since 2010. Such shareholder-friendly policies of the company reflect a strong liquidity position.
Honeywell & KE2 Therm to Cut Energy Costs for Retail Grocers
by Zacks Equity Research
Honeywell's (HON) partnership with KE2 Therm will help retail grocers to reduce energy costs and wastage apart from meeting regulatory instructions.
Danaher (DHR) Plans to Redeem $875M Worth of Senior Notes
by Zacks Equity Research
Danaher (DHR) intends to redeem $875 million worth of senior notes. Funds received from Envista will be used for note redemption.
Danaher's (DHR) Subsidiary Envista Closes IPO, Shares Up
by Zacks Equity Research
Danaher's (DHR) Envista closes its initial public offering and pays the proceeds to Danaher as part payment for its assets.
4 Stocks to Focus on Global Biotechnology Reagents Market
by Zacks Equity Research
Increased use of reagents in the field of research, bioscience and genetics is pushing the biotechnology reagents market higher.
The Zacks Analyst Blog Highlights: AbbVie, Union Pacific, CSX, Danaher and ONEOK
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AbbVie, Union Pacific, CSX, Danaher and ONEOK
Danaher's Subsidiary Envista Prices IPO, to Trade as NVST
by Zacks Equity Research
Danaher's (DHR) subsidiary, Envista, goes public with an initial offering of roughly 26.8 million shares.
Top Analyst Reports for AbbVie, Union Pacific & CSX
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including AbbVie (ABBV), Union Pacific (UNP) and CSX (CSX).
3M Launches 3M M*Modal CDI Engage One for Healthcare Market
by Zacks Equity Research
3M's (MMM) 3M M*Modal CDI Engage One offers real-time clinical insight to clinical documentation improvement specialists, clinicians and coding teams.
Honeywell (HON) Commissions Technology for Zhejiang Satellite
by Zacks Equity Research
Zhejiang Satellite uses Honeywell's (HON) C3 Oleflex technology for the production of polymer-grade propylene at its facility in China.
General Electric to Get Roughly $3B From Stake Sale in BHGE
by Zacks Equity Research
General Electric's (GE) offering of Baker Hughes' shares to the public and Baker Hughes' decision to buy back own shares will likely raise roughly $3 billion. Funds will help in reducing debts.
Diversified Operations Industry Near-Term Prospects Bright
by Payal Jalan
Technological advancements, favorable conditions in end markets like aerospace and defense, restructuring efforts and pro-growth policies of the government are making conglomerates a favorable investment destination.
UTX or DHR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
UTX vs. DHR: Which Stock Is the Better Value Option?